AC IMMUNE SA SF-02 (IMR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AC IMMUNE SA SF-02 (IMR) has a cash flow conversion efficiency ratio of -0.368x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-16.51 Million ≈ $-19.30 Million USD) by net assets (€44.88 Million ≈ $52.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AC IMMUNE SA SF-02 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how AC IMMUNE SA SF-02's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AC IMMUNE SA SF-02 (IMR) total liabilities for a breakdown of total debt and financial obligations.
AC IMMUNE SA SF-02 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AC IMMUNE SA SF-02 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Monogram Orthopaedics Inc. Common Stock
NASDAQ:MGRM
|
-0.267x |
|
Adagene Inc
NASDAQ:ADAG
|
-0.129x |
|
Zura Bio Limited Class A Ordinary Shares
NASDAQ:ZURA
|
-0.130x |
|
Alector Inc
NASDAQ:ALEC
|
-1.360x |
|
EPACK Durable Limited
NSE:EPACK
|
-0.218x |
|
Sunrex Technology Corp
TW:2387
|
0.035x |
|
Grupa Azoty Zaklady Azotowe Pulawy SA
WAR:ZAP
|
0.246x |
|
Sizzle Acquisition Corp. II - Class A ordinary shares
NASDAQ:SZZL
|
0.000x |
Annual Cash Flow Conversion Efficiency for AC IMMUNE SA SF-02 (2021–2025)
The table below shows the annual cash flow conversion efficiency of AC IMMUNE SA SF-02 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see IMR stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €44.88 Million ≈ $52.47 Million |
€-69.26 Million ≈ $-80.97 Million |
-1.543x | -363.13% |
| 2024-12-31 | €112.27 Million ≈ $131.26 Million |
€65.84 Million ≈ $76.98 Million |
0.586x | +255.96% |
| 2023-12-31 | €160.64 Million ≈ $187.81 Million |
€-60.41 Million ≈ $-70.62 Million |
-0.376x | +13.62% |
| 2022-12-31 | €168.99 Million ≈ $197.57 Million |
€-73.57 Million ≈ $-86.01 Million |
-0.435x | -53.74% |
| 2021-12-31 | €231.98 Million ≈ $271.21 Million |
€-65.69 Million ≈ $-76.80 Million |
-0.283x | -- |
About AC IMMUNE SA SF-02
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more